Know Cancer

forgot password

Clinical Activity, Safety and Immunogenic Properties of Cancer Immunotherapeutic GSK2132231A in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma

Phase 2
18 Years
Open (Enrolling)
Neoplasms, Melanoma, Unresectable and Progressive Metastatic Cutaneous Melanoma

Thank you

Trial Information

Clinical Activity, Safety and Immunogenic Properties of Cancer Immunotherapeutic GSK2132231A in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma

Inclusion Criteria:

1. The patient (male or female) has histologically proven, measurable metastatic
cutaneous melanoma in one of the following stages according to the American Joint
Committee on Cancer classification of 2002:

- Stage III in transit, or

- Stage III unresectable, or

- Stage IV M1a.

2. There has been documented progression of the patient's disease within the 12 weeks
before the first administration of study treatment.

3. The patient presents at screening with at least 3 tumor lesions of diameter >= 0.5

4. Written informed consent has been obtained from the patient before the performance of
any protocol-specific procedure.

5. The patient is >= 18 years of age at the time of signature of informed consent.

6. The patient's tumor shows expression of MAGE-A3 gene in at least one of the two tumor
biopsies performed at baseline.

7. The patient's ECOG performance status is 0 or 1.

8. The patient has normal organ functions, as assessed by standard laboratory criteria.

9. If the patient is female, she must be of non-childbearing potential, or if she is of
childbearing potential, she must practice adequate contraception for 30 days prior to
administration of study treatment, have a negative pregnancy test and continue such
precautions during the entire study treatment period and for 2 months after
completion of the treatment injection series.

10. In the view of the investigator, the patient can and will comply with the
requirements of the protocol.

Exclusion Criteria:

1. The patient has at any time received systemic (bio)-chemotherapy

2. The patient is scheduled to receive any anti-cancer specific treatment, including
radiotherapy, immunotherapy, chemotherapy and immunomodulating agents.

3. The patient requires concomitant treatment with systemic corticosteroids, or any
other immunosuppressive agents.

4. The patient has received any cancer immunotherapeutic containing a MAGE A3 antigen or
any cancer immunotherapeutic for his/her metastatic disease.

5. Use of any investigational or non-registered product (drug or vaccine) other than the
study treatment within the 30 days preceding the first dose of study treatment, or
planned use during the study period.

6. The patient has (or has had) previous or concomitant malignancies at other sites,
except effectively treated malignancy that is considered by the investigator highly
likely to have been cured.

7. History of allergic disease or reactions likely to be exacerbated by any component of
the study investigational product.

8. The patient has an autoimmune disease such as, but not limited to, neuroinflammatory
autoimmune diseases, systemic lupus erythematosus, and inflammatory bowel disease

9. The patient has a family history of congenital or hereditary immunodeficiency.

10. The patient is known to be positive for the human immunodeficiency virus (HIV).

11. The patient has psychiatric or addictive disorders that may compromise his/her
ability to give informed consent, or to comply with the study procedures.

12. The patient has concurrent severe medical problems, unrelated to the malignancy, that
would significantly limit full compliance with the study or expose the patient to
unacceptable risk.

13. For female patients: the patient is pregnant or lactating.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Tumor response defined as objective response (complete or partial), stable disease or mixed response

Outcome Time Frame:

After the concluding visit of the last patient

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



Belgium: Agence Fédérale des Médicaments et des Produits de la Santé

Study ID:




Start Date:

May 2009

Completion Date:

December 2014

Related Keywords:

  • Neoplasms
  • Melanoma
  • Unresectable and Progressive Metastatic Cutaneous Melanoma
  • ASCI (Antigen-Specific Cancer Immunotherapeutic)
  • MAGE-A3
  • Malignant melanoma
  • Cancer immunotherapeutic
  • Neoplasms
  • Melanoma
  • Skin Neoplasms